You just read:

Neurocrine Announces Completion of Phase II Clinical Study of VMAT2 Inhibitor INGREZZA™ (valbenazine) in Adults with Tourette Syndrome

News provided by

Neurocrine Biosciences, Inc.

Jan 17, 2017, 16:01 ET